Lowest Price Guaranteed From USD 4,899
Published
May 2020
Pages
510
View Count
8365
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life. In fact, according to the World Health Organization (WHO), over 50% of the global population is currently estimated to be suffering from at least one chronic disease. The past few years have witnessed introduction of several innovative pharmaceutical interventions for the treatment of a number of such diseases. However, majority of the available treatment options require parenteral administration of the drug, frequent dosing, and involve repeated hospital visits. Treatment administration via the parenteral route is also associated with various concerns, such as dosing errors, risk of microbial contamination and needlestick injuries. These are known to be the primary factors affecting medication adherence and, thereby, have a significant impact on therapeutic outcomes. Over the past few years, a number of companies have developed advanced therapeutic delivery solutions (such as autoinjectors, pen injectors, prefilled syringes) to overcome the challenges associated with the administration of both conventional and novel drug / therapy molecules. In fact, these drug delivery devices can prove to be potential vehicles for drug administration in disease outbreaks / pandemics (such as the one being faced due to the novel corona virus / COVID-19). Amongst modern drug delivery practices, the concept of self-injection has facilitated the administration of medications outside the clinical setting. Such practices also allow reductions in healthcare costs and enable the optimal usage of healthcare resources.
Specifically, large volume wearable injectors used for subcutaneous drug delivery, have become a preferred choice for administration of drugs in the home-care setting. Variants of these wearable devices have been designed to administer highly viscous drugs (such as biologics) in large volumes (more than 1 mL), offering numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, and an almost negligible risk of needlestick injuries. Such devices have captured the interest of several stakeholders in this industry and are being used for the administration of both insulin and non-insulin drugs. The field is presently witnessing a lot of innovation, such as the development of integrated mobile applications with smart health monitoring, artificial intelligence algorithms and other interesting features (including provisions for reminders, and the ability to connect to web-based portals for sharing medical data with the concerned healthcare providers), visual / audible drug delivery confirmation notifications, automatic drug reconstitution, and error alerts. We believe that such efforts are likely to drive growth in this market over the coming years.
Scope of the Report
The “Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus , Basal and Continuous Delivery Devices” report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next ten years. It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall large volume wearable injectors market with a detailed market segmentation on the [A] type of device (patch pump, injector and infusion pump and injector), [B] usability (reusable and disposable), [C] therapeutic area (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter Outlines
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the large volume wearable injectors market in the short-mid-term and long term.
Chapter 3 provides a general introduction to large volume wearable injectors, highlighting the growing demand for medical devices that enable self-administration. The chapter lays emphasis on the need for such devices, in terms of the rising incidence and prevalence of chronic diseases. Additionally, it provides an overview of the different types of self-injection devices available in the market, listing their various advantages. It also features a brief discussion on the concerns related to the use of such devices.
Chapter 4 presents information on the large volume wearable injectors that are capable of delivering drugs and drug device combinations designed for delivery of specific drugs. In addition, the chapter includes a detailed analysis of these injector devices based on the status of development, type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. In addition, the chapter provides a list of the large volume wearable injectors for delivery of insulin, along with the information on the aforementioned parameters and availability of prefilled insulin cartridges, availability of CGM / BGM systems, availability of Automated Insulin Delivery Feature and type of remote control features (control within device / PDM / smartphone).
Chapter 5 presents a detailed competitiveness analysis of large volume wearable injectors based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
Chapter 6 provides detailed profiles of the key players that develop large volume wearable injectors. Each profile presents a brief overview of the company, financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 7 provides tabulated profiles of drug device combination products. Each profile includes drug specifications, mechanism of action, current status of development, dosage and sales information.
Chapter 8 features an in-depth analysis and discussion on the various partnerships inked between the players in this market in the time period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types of deals.
Chapter 9 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
Chapter 10 provides an in-depth patent analysis, presenting an overview of the filed / granted patents related to wearable injectors for the delivery of drugs in large volumes. For this analysis, we looked at the patents that have been published by various players over the last three decades. The analysis highlights the key information and trends associated with these patents, including patent type (granted patents, patent applications and others), patent publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of players (industry and non-industry players) and the leading industry players, non-industry players and individual patent assignees. The chapter also includes a patent benchmarking analysis and patent valuation analysis.
Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via large volume wearable injectors in the future, identified on the basis of an analysis of the potential candidates, taking into consideration the various parameters, such as stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular / intravenous). Additionally, we compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a large volume wearable injector in the future was estimated using the weighted average method.
Chapter 12 provides insights on the popularity of large volume wearable injectors on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords / phrases and social media activity of the most popular players with the comparison of the tweets associated with their product. It also presents a bubble analysis of the most influential authors related to large volume wearable injectors on Twitter.
Chapter 13 presents a comprehensive clinical trial analysis of the complete and active studies being conducted to evaluate the combinations of drugs and large volume wearable injectors based on the various parameters, such as trial registration year, current trial phase, current trial status, study design, study focus, targeted therapeutic area and clinical endpoints.
Chapter 14 includes a brief case study on the role of contract manufacturing organizations in the overall manufacturing process / supply chain of a wearable injector. It includes information on the services provided by such organizations for manufacturing of device components (primary containers), infusion sets, adhesives, closures and injection moldings. In addition, it includes a schematic world map representation highlighting the location of the CMOs and their device manufacturing service portfolio.
Chapter 15 features a discussion on the various guidelines established by major regulatory bodies for medical device approvals across North America (the US, Canada and Mexico), Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of large volume wearable injectors (for delivery of non-insulin drugs) till the year 2030. We have segregated the opportunity on the basis of the type of device (patch pump, injector and infusion pump and injector), usability (reusable and disposable), key therapeutic areas (neurological disorders, cardiovascular disorders, infectious disease, oncological disorders and others) and key geographies (North America, Europe, Asia Pacific and rest of the world). In addition, the chapter presents an opportunity analysis of the market for large volume wearable injectors for delivery of insulin, till the year 2030.
Chapter 17 presents a detailed discussion on the future opportunities of wearable injectors for large volume drug delivery. It also highlights the key parameters and trends that are likely to influence the future of this market, under a detailed SWOT framework.
Chapter 18 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Jesper Roested (CEO, Subcuject), Mindy Katz (Director of Product, Sorrel Medical), Menachem Zucker (VP and Chief Scientist, Elcam Medical), Graham Reynolds (VP and GM, Biologics, West Pharmaceutical Services), Mark Banister (CEO, Medipacs), Michael Hooven (CEO, Enable Injections) and Pieter Muntendam (former President and CEO, scPharmaceuticals).
Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 20 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Drug Delivery Devices
3.3. Conventional Parenteral Drug Delivery
3.3.1 Needlestick Injuries
3.3.1.1. Incidence and Cost Burden
3.3.1.2. Prevention of Needlestick Injuries
3.3.1.3. Government Legislations for the Prevention of Needlestick Injuries
3.4. Emergence of Self-Administration Devices
3.4.1. Driving Factors
3.4.1.1. Rising Burden of Chronic Diseases
3.4.1.2. Healthcare Cost Savings
3.4.1.3. Need for Immediate Treatment in Emergency Situations
3.4.1.4. Growing Injectable Drugs Market
3.4.1.5. Rising Focus on Patient Centricity
3.4.1.6. Need for Improving Medication Adherence
3.5. Available Self-Injection Devices
3.5.1. Prefilled Syringes
3.5.2. Pen-Injectors
3.5.3. Needle-Free Injectors
3.5.4. Autoinjectors
3.5.5. Large Volume Wearable Injectors
3.6. Regulatory Considerations
3.6.1. Medical Devices
3.6.2. Drug Device Combination Products
3.7. Future Perspectives of Self-Injection Systems
4. LARGE VOLUME WEARABLE INJECTORS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Large Volume Wearable Injectors: Overall Market Landscape
4.2.1. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape
4.2.1.1. Analysis by Stage of Development
4.2.1.2. Analysis by Type of Device
4.2.1.3. Analysis by Type of Dose
4.2.1.4. Analysis by Route of Administration
4.2.1.5. Analysis by Mode of Injection
4.2.1.6. Analysis by Volume / Storage Capacity
4.2.1.7. Analysis by Actuation Mechanism
4.2.1.8. Analysis by Usability
4.2.1.9. Analysis by Availability of Prefilled Drug Reservoir
4.2.1.10. Analysis by Availability of Connectivity
4.2.2. Large Volume Drug Device Combinations: Market Landscape
4.2.2.1. Analysis by Stage of Development
4.2.2.2. Analysis by Type of Device
4.2.2.3. Analysis by Drug Compatibility
4.2.2.4. Analysis by Type of Dose
4.2.2.5. Analysis by Route of Administration
4.2.2.6. Analysis by Mode of Injection
4.2.2.7. Analysis by Therapeutic Area
4.2.2.8. Analysis by Volume / Storage Capacity
4.2.2.9. Analysis by Usability
4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices and Drug Device Combinations)
4.2.3.1. Analysis by Year of Establishment
4.2.3.2. Analysis by Company Size
4.2.3.3. Analysis by Geography
4.2.4. Large Volume Wearable Injectors for Insulin: Market Landscape
4.2.4.1. Analysis by Stage of Development
4.2.4.2. Analysis by Type of Device
4.2.4.3. Analysis by Volume / Storage Capacity
4.2.4.4. Analysis by Usability
4.2.4.5. Analysis by Availability of Prefilled Insulin Cartridges
4.2.4.6. Analysis by Availability of CGM / BGM System
4.2.4.7. Analysis by Availability of Automated Insulin Delivery (AID) Feature
4.2.4.8. Analysis by Availability of Connectivity
4.2.4.9. Analysis by Type of Remote Control Features
4.2.5. Large Volume Wearable Injectors for Insulin: Analysis of Developers
4.2.5.1. Analysis by Year of Establishment
4.2.5.2. Analysis by Company Size
4.2.5.3. Analysis by Geography
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Product Competitiveness Analysis
5.3.1. Large Volume Wearable Injectors for Non-Insulin Drugs
5.3.2. Large Volume Drug Device Combinations
5.3.3. Large Volume Wearable Injectors for Insulin
6. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS
6.1. Chapter Overview
6.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players
6.2.1. Becton Dickinson
6.2.1.1. Company Snapshot
6.2.1.2. Product Portfolio
6.2.1.3. Financial Information
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Bespak
6.2.2.1. Company Snapshot
6.2.2.2. Product Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Enable Injections
6.2.3.1. Company Snapshot
6.2.3.2. Product Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Insulet
6.2.4.1. Company Snapshot
6.2.4.2. Product Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Roche
6.2.5.1. Company Snapshot
6.2.5.2. Product Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Sensile Medical
6.2.6.1. Company Snapshot
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.2.7. Sonceboz
6.2.7.1. Company Snapshot
6.2.7.2. Product Portfolio
6.2.7.3. Recent Developments and Future Outlook
6.2.8. SteadyMed Therapeutics
6.2.8.1. Company Snapshot
6.2.8.2. Product Portfolio
6.2.8.3. Recent Developments and Future Outlook
6.2.9. Weibel CDS
6.2.9.1. Company Snapshot
6.2.9.2. Product Portfolio
6.2.9.3. Recent Developments and Future Outlook
6.2.10. West Pharmaceutical Services
6.2.10.1. Company Snapshot
6.2.10.2. Product Portfolio
6.2.10.3. Financial Information
6.2.10.4. Recent Developments and Future Outlook
6.3. Large Volume Wearable Injectors for Insulin: Key Players
6.3.1. CeQur
6.3.1.1. Company Snapshot
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Debiotech
6.3.2.1. Company Snapshot
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Eli Lilly
6.3.3.1. Company Snapshot
6.3.3.2. Product Portfolio
6.3.3.3. Financial Information
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medtronic
6.3.4.1. Company Snapshot
6.3.4.2. Product Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook
6.3.5. PharmaSens
6.3.5.1. Company Snapshot
6.3.5.2. Product Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. SOOIL Development
6.3.6.1. Company Snapshot
6.3.6.2. Product Portfolio
6.3.6.3. Recent Developments and Future Outlook
6.3.7. Tandem Diabetes Care
6.3.7.1. Company Snapshot
6.3.7.2. Product Portfolio
6.3.7.3. Financial Information
6.3.7.4. Recent Developments and Future Outlook
7. DRUG-DEVICE COMBINATIONS: TABULATED PROFILES
7.1. Chapter Overview
7.2. Apomorphine / D-mine® Pump
7.3. Apomorphine / ND0701
7.4. Bupivacaine / SMT-301
7.5. Ceftriaxone / sc2Wear® Infusor
7.6. Furosemide / 3 mL Micropump
7.7. Furosemide / FUROSCIX® On-body Infusor
7.8. Herceptin® / Single Use Injector
7.9. Ketorolac / SMT-201
7.10. Levodopa and Carbidopa / ND0612 and ND0901
7.11. Lutrepulse / The LUTREPULSE® System
7.12. Neulasta® / Neulasta OnPro™ On-body Injector
7.13. Repatha® / Pushtronex® System
7.14. Treprostinil / Trevyent®
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Large Volume Wearable Injectors: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Device
8.3.4. Analysis by Year of Partnership and Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Regional Analysis
8.3.8. Intercontinental and Intracontinental Agreements
9. KEY ACQUISITION TARGETS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Potential Strategic Acquisition Targets for Non-Insulin Drug Delivery Players
9.5. Potential Strategic Acquisition Targets for Insulin Drug Delivery Players
9.6. Concluding Remarks
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Large Volume Wearable Injectors: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Issuing Authority / Patent Offices Involved
10.3.3. Analysis by CPC Symbols
10.3.4. Emerging Focus Areas
10.3.5. Analysis by Type of Industry
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Large Volume Wearable Injectors: Patent Valuation Analysis
11. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs
11.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
11.3. Clinical Drug Candidates
11.3.1. Biologics
11.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2. Small Molecules
11.3.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
11.3.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors
12. EMERGING TRENDS ON SOCIAL MEDIA
12.1. Chapter Overview
12.2. Large Volume Wearable Injectors: Trends on Twitter
12.2.1. Historical Trend in Volume of Tweets
12.2.2. Trending Words / Phrases Related to Large Volume Wearable Injectors
12.2.3. Most Influential Authors
12.2.4. Popular Players on Twitter
12.2.4.1. Roche (Accu-Chek® Solo Micropump System)
12.2.4.2. Insulet (Omnipod®)
12.2.4.3. Medtronic (MiniMed® Wearable Injectors)
12.2.4.4. Comparison of Popular Players Based on Number of Tweets
12.3. Concluding Remarks
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Large Volume Wearable Injectors: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Trial Registration and Number of Patients Enrolled
13.3.5. Analysis by Study Design
13.3.6. Analysis by Type of Sponsor / Collaborator
13.3.7. Leading Players: Analysis by Number of Registered Trials
13.3.8. Word Cloud: Key Focus Areas
13.3.9. Analysis by Therapeutic Area
13.3.10. Popular Drug Device Combinations: Analysis by Number of Registered Trials
13.3.11. Geographical Analysis by Number of Registered Trials
13.3.12. Geographical Analysis by Patients Enrolled
13.3.13. Analysis by Clinical Endpoints
14. CASE STUDY: ROLE OF CMOs IN DEVICE DEVELOPMENT SUPPLY CHAIN
14.1. Chapter Overview
14.2. Device Development Supply Chain
14.3. Significance of CMOs in the Drug Delivery Device Development Process
14.4. List of Contract Manufacturing Organizations
14.4.1. Contract Manufacturers: Geographical Distribution and Services Offered
15. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
15.1. Chapter Overview
15.2. General Regulatory and Reimbursement Guidelines for Medical Devices
15.3. Regulatory and Reimbursement Landscape in North America
15.3.1. The US Scenario
15.3.1.1. Regulatory Authority
15.3.1.2. Review / Approval Process
15.3.1.3. Reimbursement Landscape
15.3.1.3.1. Payer Mix
15.3.1.3.2. Reimbursement Process
15.3.2. The Canadian Scenario
15.3.2.1. Regulatory Authority
15.3.2.2. Review / Approval Process
15.3.2.3. Reimbursement Landscape
15.3.2.3.1. Payer Mix
15.3.2.3.2. Reimbursement Process
15.3.3. The Mexican Scenario
15.3.3.1. Regulatory Authority
15.3.3.2. Review / Approval Process
15.3.3.3. Reimbursement Landscape
15.3.3.3.1. Payer Mix
15.4. Regulatory and Reimbursement Landscape in Europe
15.4.1. Overall Scenario
15.4.1.1. Overall Regulatory Authority
15.4.1.2. Overall Review / Approval Process
15.4.2. The UK Scenario
15.4.2.1. Regulatory Authority
15.4.2.2. Review / Approval Process
15.4.2.3. Reimbursement Landscape
15.4.2.3.1. Payer Mix
15.4.2.3.2. Reimbursement Process
15.4.3. The French Scenario
15.4.3.1. Regulatory Authority
15.4.3.2. Review / Approval Process
15.4.3.3. Reimbursement Landscape
15.4.3.3.1. Payer Mix
15.4.3.3.2. Reimbursement Process
15.4.4. The German Scenario
15.4.4.1. Regulatory Authority
15.4.4.2. Review / Approval Process
15.4.4.3. Reimbursement Landscape
15.4.4.3.1. Payer Mix
15.4.4.3.2. Reimbursement Process
15.4.5. The Italian Scenario
15.4.5.1. Regulatory Authority
15.4.5.2. Review / Approval Process
15.4.5.3. Reimbursement Landscape
15.4.5.3.1. Payer Mix
15.4.5.3.2. Reimbursement Process
15.4.6. The Spanish Scenario
15.4.6.1. Regulatory Authority
15.4.6.2. Review / Approval Process
15.4.6.3. Reimbursement Landscape
15.4.6.3.1. Payer Mix
15.4.6.3.2. Reimbursement Process
15.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
15.5.1. The Australian Scenario
15.5.1.1. Regulatory Authority
15.5.1.2. Review / Approval Process
15.5.1.3. Reimbursement Landscape
15.5.1.3.1. Payer Mix
15.5.1.3.2. Reimbursement Process
15.5.2. The Brazilian Scenario
15.5.2.1. Regulatory Authority
15.5.2.2. Review / Approval Process
15.5.2.3. Reimbursement Landscape
15.5.2.3.1. Payer Mix
15.5.2.3.2. Reimbursement Process
15.5.3. The Chinese Scenario
15.5.3.1. Regulatory Authority
15.5.3.2. Review / Approval Process
15.5.3.3. Reimbursement Landscape
15.5.3.3.1. Payer Mix
15.5.3.3.2. Reimbursement Process
15.5.4. The Indian Scenario
15.5.4.1. Regulatory Authority
15.5.4.2. Review / Approval Process
15.5.4.3. Reimbursement Landscape
15.5.4.3.1. Payer Mix
15.5.5. The Israeli Scenario
15.5.5.1. Regulatory Authority
15.5.5.2. Review / Approval Process
15.5.5.3. Reimbursement Landscape
15.5.5.3.1. Payer Mix
15.5.6. The Japanese Scenario
15.5.6.1. Regulatory Authority
15.5.6.2. Review / Approval Process
15.5.6.3. Reimbursement Landscape
15.5.6.3.1. Payer Mix
15.5.6.3.2. Reimbursement Process
15.5.7. The New Zealand Scenario
15.5.7.1. Regulatory Authority
15.5.7.2. Review / Approval Process
15.5.7.3. Reimbursement Landscape
15.5.7.3.1. Payer Mix
15.5.7.3.2. Reimbursement Process
15.5.8. The Singaporean Scenario
15.5.8.1. Regulatory Authority
15.5.8.2. Review / Approval Process
15.5.8.3. Reimbursement Landscape
15.5.8.3.1. Payer Mix
15.5.8.3.2. Reimbursement Process
15.5.9. The South Korea Scenario
15.5.9.1. Regulatory Authority
15.5.9.2. Review / Approval Process
15.5.9.3. Reimbursement Landscape
15.5.9.3.1. Payer Mix
15.5.9.3.2. Reimbursement Process
15.5.10. The South African Scenario
15.5.10.1. Regulatory Authority
15.5.10.2. Review / Approval Process
15.5.10.3. Reimbursement Landscape
15.5.11. The Taiwanese Scenario
15.5.11.1. Regulatory Authority
15.5.11.2. Review / Approval Process
15.5.11.3. Reimbursement Landscape
15.5.11.3.1. Payer Mix
15.5.11.3.2. Reimbursement Process
15.5.12. The Thailand Scenario
15.5.12.1. Regulatory Authority
15.5.12.2. Review / Approval Process
15.5.12.3. Reimbursement Landscape
15.6. Comparison of Regional Regulatory Environment
15.7. Concluding Remarks
16. MARKET SIZING AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Value)
16.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Value)
16.3.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Value)
16.3.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.4 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Value)
16.4.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Value)
16.4.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Value)
16.4.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Value)
16.5.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Value)
16.5.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Value)
16.5.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.6.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.6.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.6.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.7. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Volume)
16.7.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Volume)
16.7.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Volume)
16.7.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Volume)
16.8.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Volume)
16.8.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Volume)
16.8.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Volume)
16.9.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Volume)
16.9.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Volume)
16.9.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Volume)
16.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)
16.10.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.10.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.10.3 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)
16.11. Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (By Value)
16.11.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (By Value)
16.11.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (By Value)
16.12 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (By Value)
16.12.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (By Value)
16.12.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (By Value)
16.13 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (By Value)
16.13.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (By Value)
16.13.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (By Value)
16.14 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (By Value)
16.14.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)
16.14.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
16.15 Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (by Volume) (By Value)
16.15.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (By Volume)
16.15.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (By Volume)
16.16 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (By Volume)
16.16.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (By Volume)
16.16.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (By Volume)
16.17 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (By Volume)
16.17.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (By Volume)
16.17.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (By Volume)
16.18 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (By Volume)
16.18.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Volume)
16.18.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. SWOT Analysis
17.2.1. Strengths
17.2.2. Weaknesses
17.2.3. Opportunities
17.2.4. Threats
17.3. Large Volume Wearable Injectors: Future Growth Opportunities
17.3.1. Rising Focus on Self-Administration of Drugs
17.3.2. Possibility of Integration with Mobile Applications
17.3.3. Potential Life Cycle Management Tool
17.3.4. Potential Usability for Multiple Therapeutic Areas
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Subcuject
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Jesper Roested, Chief Executive Officer
18.3. Sorrel Medical
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Mindy Katz, Director of Product
18.4. Elcam Medical
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
18.5. West Pharmaceutical Services
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Graham Reynolds, Vice President and General Manager, Biologics
18.6. Medipacs
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Mark Banister, Chief Executive Officer
18.7. Enable Injections
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Michael Hooven, Chief Executive Officer
18.8. scPharmaceuticals
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer
19. CONCLUDING REMARKS
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Evolution of Healthcare Safety Legislations
Figure 3.3 Large Volume Wearable Injectors Market: Driving Factors
Figure 3.4 Types of Self-Injection Devices
Figure 4.1 Large Volume Wearable Injectors: Overall Market Landscape
Figure 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Stage of Development
Figure 4.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Device
Figure 4.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Dose
Figure 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Route of Administration
Figure 4.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Mode of Injection
Figure 4.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Volume / Storage Capacity
Figure 4.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Actuation Mechanism
Figure 4.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Usability
Figure 4.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Availability of Prefilled Drug Reservoir
Figure 4.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Connectivity
Figure 4.12 Large Volume Drug Device Combinations: Analysis by Stage of Development
Figure 4.13 Large Volume Drug Device Combinations: Analysis by Type of Device
Figure 4.14 Large Volume Drug Device Combinations: Analysis by Drug Compatibility
Figure 4.15 Large Volume Drug Device Combinations: Analysis by Type of Dose
Figure 4.16 Large Volume Drug Device Combinations: Analysis by Route of Administration
Figure 4.17 Large Volume Drug Device Combinations: Analysis by Mode of Injection
Figure 4.18 Large Volume Drug Device Combinations: Analysis by Therapeutic Area
Figure 4.19 Large Volume Drug Device Combinations: Analysis by Volume / Storage Capacity
Figure 4.20 Large Volume Drug Device Combinations: Analysis by Usability
Figure 4.21 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Year of Establishment (Devices and Drug Device Combinations)
Figure 4.22 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Size (Devices and Drug Device Combinations)
Figure 4.23 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Geography (Devices and Drug Device Combinations)
Figure 4.24 Large Volume Wearable Injectors for Insulin: Analysis by Stage of Development
Figure 4.25 Large Volume Wearable Injectors for Insulin: Analysis by Type of Device
Figure 4.26 Large Volume Wearable Injectors for Insulin: Analysis by Volume / Storage Capacity
Figure 4.27 Large Volume Wearable Injectors for Insulin: Analysis by Usability
Figure 4.28 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Prefilled Insulin Cartridges
Figure 4.29 Large Volume Wearable Injectors for Insulin: Analysis by Availability of CGM / BGM System
Figure 4.30 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Automated Insulin Delivery (AID) Feature
Figure 4.31 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Connectivity
Figure 4.32 Large Volume Wearable Injectors for Insulin: Analysis by Type of Remote Control Features
Figure 4.33 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Year of Establishment
Figure 4.34 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Size
Figure 4.35 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Geography
Figure 5.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 5.2 Product Competitiveness Analysis: Large Volume Drug Device Combinations
Figure 5.3 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 8.2 Partnerships and Collaborations: Analysis by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Device
Figure 8.5 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 8.6 Most Active Players: Analysis by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Analysis
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Publication Year
Figure 10.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 10.4 Patent Analysis: Distribution by CPC Symbols
Figure 10.5 Patent Analysis: Emerging Focus Areas
Figure 10.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.7 Patent Analysis: Leading Industry Players
Figure 10.8 Patent Analysis: Leading Non-Industry Players
Figure 10.9 Patent Analysis: Leading Individual Assignees
Figure 10.10 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Figure 10.11 Patent Analysis: Distribution of Patents by Age
Figure 10.12 Large Volume Wearable Injectors: Patent Valuation
Figure 12.1 Social Media Analysis: Historical Trend related to Large Volume Wearable Injectors on Twitter
Figure 12.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 12.3 Social Media Analysis: Most Influential Authors on Twitter
Figure 12.4 Social Media Analysis: Comparison of Popular Players on Twitter
Figure 12.5 Social Media Activity of Roche
Figure 12.6 Social Media Activity of Insulet
Figure 12.7 Social Media Activity of Medtronic
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 13.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Figure 13.4 Clinical Trial Analysis: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020
Figure 13.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 13.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 13.7 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2002-2019
Figure 13.8 Clinical Trial Analysis: Distribution by Study Design
Figure 13.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 13.10 Leading Players: Analysis by Number of Registered Trials
Figure 13.11 Word Cloud Analysis: Distribution by Focus Area
Figure 13.12 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 13.13 Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
Figure 13.14 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Large Volume
Figure 13.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 13.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 13.17 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 14.1 CMOs for Large Volume Wearable Injectors: Market Landscape and Services Offered
Figure 15.1 Key Regulatory Authorities for Medical Devices
Figure 15.2 Medical Devices Review / Approval Process: US
Figure 15.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 15.4 Medical Devices National Coverage Determination Process: US
Figure 15.5 Medical Devices Review / Approval Process: Canada
Figure 15.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 15.7 Medical Devices Review / Approval Process: Mexico
Figure 15.8 Regulatory Bodies in EU5 Countries
Figure 15.9 Steps involved in CE Marking Process
Figure 15.10 Medical Devices Review / Approval Process: Europe
Figure 15.11 Medical Devices Review / Approval Process: UK
Figure 15.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 15.13 Medical Devices Reimbursement Process: UK
Figure 15.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 15.15 Medical Devices Reimbursement Process: France
Figure 15.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 15.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 15.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 15.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 15.20 Medical Devices Reimbursement Process: Italy
Figure 15.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 15.22 Medical Devices Reimbursement Process: Spain
Figure 15.23 Medical Devices Review / Approval Process: Australia
Figure 15.24 Healthcare Insurance Coverage in Australia: Percentage Distribution by Type of Coverage
Figure 15.25 Medical Devices Review / Approval Process: Brazil
Figure 15.26 Medical Devices Reimbursement Process: Brazil
Figure 15.27 Medical Devices Review / Approval Process: China
Figure 15.28 Healthcare Insurance Coverage in China: Percentage Distribution by Type of Coverage
Figure 15.29 Medical Devices Reimbursement Process: Shanghai
Figure 15.30 Medical Devices Review / Approval Process: India
Figure 15.31 Healthcare Insurance Coverage in Israel: Percentage Distribution by Type of Coverage
Figure 15.32 Medical Devices Review / Approval Process: Japan
Figure 15.33 Medical Devices Reimbursement Process: Japan
Figure 15.34 Healthcare Insurance Coverage in Japan: Percentage Distribution by Type of Coverage
Figure 15.35 New Medical Devices Reimbursement Process: Japan
Figure 15.36 Medical Devices Review / Approval Process: New Zealand
Figure 15.37 Healthcare Insurance Coverage in New Zealand: Percentage Distribution by Type of Coverage
Figure 15.38 Medical Devices Review / Approval Process: Singapore
Figure 15.39 Medical Devices Review / Approval Process: South Korea
Figure 15.40 Healthcare Insurance Coverage in South Korea: Percentage Distribution by Type of Coverage
Figure 15.41 Medical Devices Review / Approval Process: South Africa
Figure 15.42 Medical Devices Review / Approval Process: Taiwan
Figure 15.43 Healthcare Insurance Coverage in Taiwan: Percentage Distribution by Type of Coverage
Figure 15.44 Medical Devices Review / Approval Process: Thailand
Figure 15.45 Heat Map Analysis: Comparison of Regional Regulatory Control for Medical Devices
Figure 15.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 16.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (USD Million)
Figure 16.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (USD Million)
Figure 16.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (USD Million)
Figure 16.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (USD Million)
Figure 16.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 16.17 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (Units, Million)
Figure 16.18 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.19 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.20 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (Units, Million)
Figure 16.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.25 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (Units, Million)
Figure 16.26 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.27 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.28 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (Units, Million)
Figure 16.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (Units, Million)
Figure 16.33 Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (USD Million)
Figure 16.34 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.35 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.36 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (USD Million)
Figure 16.37 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.38 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.39 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (USD Million)
Figure 16.40 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.41 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.42 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (USD Million)
Figure 16.43 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (USD Million)
Figure 16.44 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 16.45 Global Large Volume Wearable Injectors Market for Insulin, 2020-2030 (Units, Million)
Figure 16.46 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.47 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.48 Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030 (Units, Million)
Figure 16.49 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.50 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.51 Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030 (Units, Million)
Figure 16.52 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.53 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 16.54 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030 (Units, Million)
Figure 16.55 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030 (Units, Million)
Figure 16.56 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Table 3.1 List of Prefilled Syringes
Table 3.2 List of Pen-Injector Systems
Table 3.3 List of Autoinjector Systems
Table 3.4 List of Needle-Free Injectors
Table 4.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.3 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Development Status and Device Features
Table 4.4 Large Volume Drug Device Combinations for Non-Insulin Drugs: Information on Administration Related Parameters
Table 4.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Developers (Both Devices and Drug Device Combinations)
Table 4.6 Large Volume Wearable Injectors for Insulin: Information on Development Status and Device Features
Table 4.7 Large Volume Wearable Injectors for Insulin: Information on Device Monitoring and Connectivity Features
Table 4.8 Large Volume Wearable Injectors for Insulin: Information on Developers
Table 6.1 Large Volume Wearable Injectors for Non-Insulin Drugs: List of Players Profiled
Table 6.2 Large Volume Wearable Injectors for Insulin: List of Players Profiled
Table 6.3 Becton Dickinson: Medical Devices Portfolio
Table 6.4 Becton Dickinson: Recent Developments and Future Outlook
Table 6.5 Bespak: Recent Developments and Future Outlook
Table 6.6 Enable Injections: Recent Developments and Future Outlook
Table 6.7 Insulet: Recent Developments and Future Outlook
Table 6.8 Roche: Recent Developments and Future Outlook
Table 6.9 Sensile Medical: Medical Devices Portfolio
Table 6.10 Sensile Medical: Recent Developments and Future Outlook
Table 6.11 Sonceboz: Medical Devices Portfolio
Table 6.12 Sonceboz: Recent Developments and Future Outlook
Table 6.13 SteadyMed Therapeutics: Medical Devices Portfolio
Table 6.14 SteadyMed Therapeutics: Recent Developments and Future Outlook
Table 6.15 Weibel CDS: Medical Devices Portfolio
Table 6.16 Weibel CDS: Recent Developments and Future Outlook
Table 6.17 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 6.18 CeQur: Recent Developments and Future Outlook
Table 6.19 Debiotech: Medical Devices Portfolio
Table 6.20 Debiotech: Recent Developments and Future Outlook
Table 6.21 Eli Lilly: Recent Developments and Future Outlook
Table 6.22 Medtronic: Recent Developments and Future Outlook
Table 6.23 SOOIL Development: Recent Developments and Future Outlook
Table 6.24 Tandem Diabetes Care: Features of slim X2 Insulin Pump
Table 6.25 Tandem Diabetes Care: Technology Portfolio
Table 6.26 Tandem Diabetes Care: Recent Developments and Future Outlook
Table 7.1 Large Volume Drug Device Combination: Apomorphine / D-mine® Pump
Table 7.2 Large Volume Drug Device Combination: Apomorphine / ND0701
Table 7.3 Large Volume Drug Device Combination: Bupivacaine / SMT-301
Table 7.4 Large Volume Drug Device Combination: Ceftriaxone / sc2Wear® Infusor
Table 7.5 Large Volume Drug Device Combination: Furosemide / 3 mL Micropump
Table 7.6 Large Volume Drug Device Combination: Furosemide / FUROSCIX® On-body Infusor
Table 7.7 Large Volume Drug Device Combination: Herceptin® SC / Roche’s Injector Device
Table 7.8 Large Volume Drug Device Combination: Ketorolac / SMT-201
Table 7.9 Large Volume Drug Device Combination: Levadopa and Carbidopa / ND0612 and ND0901
Table 7.10 Large Volume Drug Device Combination: Lutrepulse / The LUTREPULSE® System
Table 7.11 Large Volume Drug Device Combination: Neulasta® / Neulasta OnPro™ On- body Injector
Table 7.12 Large Volume Drug Device Combination: Repatha® / Pushtronex® System
Table 7.13 Large Volume Drug Device Combination: Treprostinil / Trevyent®
Table 8.1 Large Volume Wearable Injectors: List of Partnerships and Collaborations
Table 10.1 Patent Analysis: CPC Symbol Definitions
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Most Popular CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Marketed Molecules: Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.2 Marketed Molecules: Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.3 Marketed Molecules: Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.4 Marketed Molecules: Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.5 Clinical Drug Candidates (Biologics): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.6 Clinical Drug Candidates (Biologics): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.7 Clinical Drug Candidates (Biologics): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.8 Clinical Drug Candidates (Biologics): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.9 Clinical Drug Candidates (Small Molecules): Most Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.10 Clinical Drug Candidates (Small Molecules): Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.11 Clinical Drug Candidates (Small Molecules): Less Likely Candidates for Delivery via Large Volume Wearable Injectors
Table 11.12 Clinical Drug Candidates (Small Molecules): Unlikely Candidates for Delivery via Large Volume Wearable Injectors
Table 14.1 List of Contract Manufacturing Organizations
Table 15.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 15.2 Device Classification: US
Table 15.3 Device Classification: Canada
Table 15.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 15.5 Device Classification: Mexico
Table 15.6 Device Classification: Europe
Table 15.7 List of CE Directives in Europe
Table 15.8 Conformity Assessment Modules in Europe
Table 15.9 Device Classification: Australia
Table 15.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 15.11 Device Classification: Brazil
Table 15.12 Device Classification: China
Table 15.13 Device Classification: India
Table 15.14 Device Classification: Japan
Table 15.15 Medical Devices Reimbursement Categories
Table 15.16 Device Classification: Medsafe
Table 15.17 Device Classification: Singapore
Table 15.18 Device Classification: South Korea
Table 15.19 Device Classification: South Africa
Table 15.20 Device Classification: Thailand
Table 15.21 Medical Devices Regulatory Landscape Summary
Table 15.22 Medical Devices Reimbursement Landscape Summary
Table 16.1 Large Volume Drug Device Combinations: List of Approved / Under Development Products
Table 16.2 Large Volume Wearable Injectors for Insulin Delivery: Annual Treatment Cost Information
Table 18.1 Company Snapshot: Subcuject
Table 18.2 Company Snapshot: Sorrel Medical
Table 18.3 Company Snapshot: Elcam Medical
Table 18.4 Company Snapshot: West Pharmaceutical Services
Table 18.5 Company Snapshot: Medipacs
Table 18.6 Company Snapshot: Enable Injections
Table 18.7 Company Snapshot: scPharmaceuticals
Table 20.1 Large Volume Wearable Injectors: Overall Market Landscape
Table 20.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Stage of Development
Table 20.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Device
Table 20.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Type of Dose
Table 20.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Route of Administration
Table 20.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Mode of Injection
Table 20.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Volume / Storage Capacity
Table 20.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Actuation Mechanism
Table 20.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Usability
Table 20.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Availability of Prefilled Drug Reservoir
Table 20.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis by Connectivity
Table 20.12 Large Volume Drug Device Combinations: Analysis by Stage of Development
Table 20.13 Large Volume Drug Device Combinations: Analysis by Type of Device
Table 20.14 Large Volume Drug Device Combinations: Analysis by Drug Compatibility
Table 20.15 Large Volume Drug Device Combinations: Analysis by Type of Dose
Table 20.16 Large Volume Drug Device Combinations: Analysis by Route of Administration
Table 20.17 Large Volume Drug Device Combinations: Analysis by Mode of Injection
Table 20.18 Large Volume Drug Device Combinations: Analysis by Therapeutic Area
Table 20.19 Large Volume Drug Device Combinations: Analysis by Volume / Storage Capacity
Table 20.20 Large Volume Drug Device Combinations: Analysis by Usability
Table 20.21 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Year of Establishment (Devices and Drug Device Combinations)
Table 20.22 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Size (Devices and Drug Device Combinations)
Table 20.23 Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers by Geography (Devices and Drug Device Combinations)
Table 20.24 Large Volume Wearable Injectors for Insulin: Analysis by Stage of Development
Table 20.25 Large Volume Wearable Injectors for Insulin: Analysis by Type of Device
Table 20.26 Large Volume Wearable Injectors for Insulin: Analysis by Volume / Storage Capacity
Table 20.27 Large Volume Wearable Injectors for Insulin: Analysis by Usability
Table 20.28 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Prefilled Insulin Cartridges
Table 20.29 Large Volume Wearable Injectors for Insulin: Analysis by Availability of CGM / BGM System
Table 20.30 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Automated Insulin Delivery (AID) Feature
Table 20.31 Large Volume Wearable Injectors for Insulin: Analysis by Availability of Connectivity
Table 20.32 Large Volume Wearable Injectors for Insulin: Distribution by Remote Control Features
Table 20.33 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Year of Establishment
Table 20.34 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Size
Table 20.35 Large Volume Wearable Injectors for Insulin: Analysis of Developers by Geography
Table 20.36 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (till March)
Table 20.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Table 20.39 Partnerships and Collaborations: Distribution by Type of Device
Table 20.40 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 20.41 Partnerships and Collaborations: Most Active Players
Table 20.42 Partnerships and Collaborations: Regional Distribution
Table 20.43 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.44 Patent Analysis: Distribution by Type of Patent
Table 20.45 Patent Analysis: Distribution by Publication Year
Table 20.46 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Table 20.47 Patent Analysis: Distribution by Type of Organization
Table 20.48 Patent Analysis: Leading Industry Players
Table 20.49 Patent Analysis: Leading Non-Industry Players
Table 20.50 Patent Analysis: Leading Individual Assignees
Table 20.51 Patent Analysis: Distribution of Patents by Age
Table 20.52 Large Volume Wearable Injectors: Patent Valuation
Table 20.53 Social Media Analysis: Most Influential Authors Related to Large Volume Wearable Injectors on Twitter
Table 20.54 Social Media Analysis: Comparison of Most Popular Players
Table 20.55 Clinical Trials: Distribution by Trial Status
Table 20.56 Clinical Trials: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Table 20.57 Clinical Trials: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020
Table 20.58 Clinical Trials: Distribution by Trial Phase
Table 20.59 Clinical Trials: Analysis by Trial Recruitment Status; Pre 2010-2019
Table 20.60 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2002-2019
Table 20.61 Clinical Trial Analysis: Distribution by Study Design
Table 20.62 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 20.63 Leading Players: Distribution by Number of Registered Trials
Table 20.64 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 20.65 Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
Table 20.66 Clinical Trial Analysis: Phase-Wise Distribution of Most Popular Large Volume Wearable Injectors
Table 20.67 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 20.68 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 20.69 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.70 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.71 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.72 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Base Scenarios, 2020-2030 (USD Million)
Table 20.73 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.74 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.75 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.76 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Table 20.77 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.78 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.79 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.80 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Table 20.81 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.82 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.83 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.84 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific and Rest of the World: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Table 20.85 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.86 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.87 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.88 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (Units, Million)
Table 20.89 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million
Table 20.90 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.91 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.92 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (Units, Million)
Table 20.93 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.94 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.95 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.96 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (Units, Million)
Table 20.97 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.98 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.99 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.100 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (Units, Million)
Table 20.101 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.102 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.103 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.104 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.105 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.106 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.107 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.108 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.109 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.110 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 20.111 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Base Scenario, 2020-2030 (USD Million)
Table 20.112 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Base Scenario, 2020-2030 (USD Million)
Table 20.113 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.114 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.115 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.116 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.117 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Base Scenario, 2020-2030 (Units Million)
Table 20.118 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.119 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.120 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.121 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Table 20.122 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (Units, Million)
Table 20.123 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Base Scenario, 2020-2030 (Units, Million)
Table 20.124 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Base Scenario, 2020-2030 (Units, Million)
Discounts available for multiple report purchases
sales@rootsanalysis.com